Selected research
Industry Research
IL-6 Receptor Antagonist Industry Research Report 2026
Market perspective
The global IL-6 Receptor Antagonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for IL-6 Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for IL-6 Receptor Antagonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for IL-6 Receptor Antagonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of IL-6 Receptor Antagonist include Biogen, EUSA Pharma, Fresenius Kabi, Hetero, Janssen Biotech, Regeneron Pharmaceuticals, Roche, R-Pharm and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global IL-6 Receptor Antagonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
IL-6 Receptor Antagonist Market by Company
Biogen
EUSA Pharma
Fresenius Kabi
Hetero
Janssen Biotech
Regeneron Pharmaceuticals
Roche
R-Pharm
Sanofi
Bio-Thera Solutions
BeiGene
Hangzhou Bozhirui Biopharmaceutical
Zhuhai Livzon Biotechnology
IL-6 Receptor Antagonist Segment by Type
Tocilizumab
Siltuximab
Sarilumab
Satralizumab
Olokizumab
Other
IL-6 Receptor Antagonist Segment by Application
Systemic Juvenile Idiopathic Arthritis
Rheumatoid Arthritis
Giant Cell Arteritis
Other
IL-6 Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-6 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-6 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-6 Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of IL-6 Receptor Antagonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of IL-6 Receptor Antagonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of IL-6 Receptor Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tocilizumab
- Siltuximab
- Sarilumab
- Satralizumab
- Olokizumab
- Other
Applications
- Systemic Juvenile Idiopathic Arthritis
- Rheumatoid Arthritis
- Giant Cell Arteritis
- Other
Companies covered
- Biogen
- EUSA Pharma
- Fresenius Kabi
- Hetero
- Janssen Biotech
- Regeneron Pharmaceuticals
- Roche
- R-Pharm
- Sanofi
- Bio-Thera Solutions
- BeiGene
- Hangzhou Bozhirui Biopharmaceutical
- Zhuhai Livzon Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global IL-6 Receptor Antagonist Market Size (2021-2032)
- 2.2.2 Global IL-6 Receptor Antagonist Sales (2021-2032)
- 2.2.3 Global IL-6 Receptor Antagonist Market Average Price (2021-2032)
- 2.3 IL-6 Receptor Antagonist by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tocilizumab
- 2.3.3 Siltuximab
- 2.3.4 Sarilumab
- 2.3.5 Satralizumab
- 2.3.6 Olokizumab
- 2.3.7 Other
- 2.4 IL-6 Receptor Antagonist by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Systemic Juvenile Idiopathic Arthritis
- 2.4.3 Rheumatoid Arthritis
- 2.4.4 Giant Cell Arteritis
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global IL-6 Receptor Antagonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global IL-6 Receptor Antagonist Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global IL-6 Receptor Antagonist Revenue of Manufacturers (2021-2026)
- 3.4 Global IL-6 Receptor Antagonist Average Price by Manufacturers (2021-2026)
- 3.5 Global IL-6 Receptor Antagonist Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of IL-6 Receptor Antagonist, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of IL-6 Receptor Antagonist, Product Type & Application
- 3.8 Global Manufacturers of IL-6 Receptor Antagonist, Established Date
- 3.9 Global IL-6 Receptor Antagonist Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biogen
- 4.1.1 Biogen Company Information
- 4.1.2 Biogen Business Overview
- 4.1.3 Biogen IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biogen IL-6 Receptor Antagonist Product Portfolio
- 4.1.5 Biogen Recent Developments
- 4.2 EUSA Pharma
- 4.2.1 EUSA Pharma Company Information
- 4.2.2 EUSA Pharma Business Overview
- 4.2.3 EUSA Pharma IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 EUSA Pharma IL-6 Receptor Antagonist Product Portfolio
- 4.2.5 EUSA Pharma Recent Developments
- 4.3 Fresenius Kabi
- 4.3.1 Fresenius Kabi Company Information
- 4.3.2 Fresenius Kabi Business Overview
- 4.3.3 Fresenius Kabi IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Fresenius Kabi IL-6 Receptor Antagonist Product Portfolio
- 4.3.5 Fresenius Kabi Recent Developments
- 4.4 Hetero
- 4.4.1 Hetero Company Information
- 4.4.2 Hetero Business Overview
- 4.4.3 Hetero IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hetero IL-6 Receptor Antagonist Product Portfolio
- 4.4.5 Hetero Recent Developments
- 4.5 Janssen Biotech
- 4.5.1 Janssen Biotech Company Information
- 4.5.2 Janssen Biotech Business Overview
- 4.5.3 Janssen Biotech IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Janssen Biotech IL-6 Receptor Antagonist Product Portfolio
- 4.5.5 Janssen Biotech Recent Developments
- 4.6 Regeneron Pharmaceuticals
- 4.6.1 Regeneron Pharmaceuticals Company Information
- 4.6.2 Regeneron Pharmaceuticals Business Overview
- 4.6.3 Regeneron Pharmaceuticals IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Regeneron Pharmaceuticals IL-6 Receptor Antagonist Product Portfolio
- 4.6.5 Regeneron Pharmaceuticals Recent Developments
- 4.7 Roche
- 4.7.1 Roche Company Information
- 4.7.2 Roche Business Overview
- 4.7.3 Roche IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche IL-6 Receptor Antagonist Product Portfolio
- 4.7.5 Roche Recent Developments
- 4.8 R-Pharm
- 4.8.1 R-Pharm Company Information
- 4.8.2 R-Pharm Business Overview
- 4.8.3 R-Pharm IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 R-Pharm IL-6 Receptor Antagonist Product Portfolio
- 4.8.5 R-Pharm Recent Developments
- 4.9 Sanofi
- 4.9.1 Sanofi Company Information
- 4.9.2 Sanofi Business Overview
- 4.9.3 Sanofi IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi IL-6 Receptor Antagonist Product Portfolio
- 4.9.5 Sanofi Recent Developments
- 4.10 Bio-Thera Solutions
- 4.10.1 Bio-Thera Solutions Company Information
- 4.10.2 Bio-Thera Solutions Business Overview
- 4.10.3 Bio-Thera Solutions IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bio-Thera Solutions IL-6 Receptor Antagonist Product Portfolio
- 4.10.5 Bio-Thera Solutions Recent Developments
- 4.11 BeiGene
- 4.11.1 BeiGene Company Information
- 4.11.2 BeiGene Business Overview
- 4.11.3 BeiGene IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 BeiGene IL-6 Receptor Antagonist Product Portfolio
- 4.11.5 BeiGene Recent Developments
- 4.12 Hangzhou Bozhirui Biopharmaceutical
- 4.12.1 Hangzhou Bozhirui Biopharmaceutical Company Information
- 4.12.2 Hangzhou Bozhirui Biopharmaceutical Business Overview
- 4.12.3 Hangzhou Bozhirui Biopharmaceutical IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Hangzhou Bozhirui Biopharmaceutical IL-6 Receptor Antagonist Product Portfolio
- 4.12.5 Hangzhou Bozhirui Biopharmaceutical Recent Developments
- 4.13 Zhuhai Livzon Biotechnology
- 4.13.1 Zhuhai Livzon Biotechnology Company Information
- 4.13.2 Zhuhai Livzon Biotechnology Business Overview
- 4.13.3 Zhuhai Livzon Biotechnology IL-6 Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Zhuhai Livzon Biotechnology IL-6 Receptor Antagonist Product Portfolio
- 4.13.5 Zhuhai Livzon Biotechnology Recent Developments
5 Global IL-6 Receptor Antagonist Market Scenario by Region
- 5.1 Global IL-6 Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global IL-6 Receptor Antagonist Sales by Region: 2021-2032
- 5.2.1 Global IL-6 Receptor Antagonist Sales by Region: 2021-2026
- 5.2.2 Global IL-6 Receptor Antagonist Sales by Region: 2027-2032
- 5.3 Global IL-6 Receptor Antagonist Revenue by Region: 2021-2032
- 5.3.1 Global IL-6 Receptor Antagonist Revenue by Region: 2021-2026
- 5.3.2 Global IL-6 Receptor Antagonist Revenue by Region: 2027-2032
- 5.4 North America IL-6 Receptor Antagonist Market Facts & Figures by Country
- 5.4.1 North America IL-6 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America IL-6 Receptor Antagonist Sales by Country (2021-2032)
- 5.4.3 North America IL-6 Receptor Antagonist Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe IL-6 Receptor Antagonist Market Facts & Figures by Country
- 5.5.1 Europe IL-6 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe IL-6 Receptor Antagonist Sales by Country (2021-2032)
- 5.5.3 Europe IL-6 Receptor Antagonist Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific IL-6 Receptor Antagonist Market Facts & Figures by Country
- 5.6.1 Asia Pacific IL-6 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific IL-6 Receptor Antagonist Sales by Country (2021-2032)
- 5.6.3 Asia Pacific IL-6 Receptor Antagonist Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America IL-6 Receptor Antagonist Market Facts & Figures by Country
- 5.7.1 South America IL-6 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America IL-6 Receptor Antagonist Sales by Country (2021-2032)
- 5.7.3 South America IL-6 Receptor Antagonist Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa IL-6 Receptor Antagonist Market Facts & Figures by Country
- 5.8.1 Middle East and Africa IL-6 Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa IL-6 Receptor Antagonist Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa IL-6 Receptor Antagonist Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global IL-6 Receptor Antagonist Sales by Type (2021-2032)
- 6.1.1 Global IL-6 Receptor Antagonist Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global IL-6 Receptor Antagonist Sales Market Share by Type (2021-2032)
- 6.2 Global IL-6 Receptor Antagonist Revenue by Type (2021-2032)
- 6.2.1 Global IL-6 Receptor Antagonist Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global IL-6 Receptor Antagonist Revenue Market Share by Type (2021-2032)
- 6.3 Global IL-6 Receptor Antagonist Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global IL-6 Receptor Antagonist Sales by Application (2021-2032)
- 7.1.1 Global IL-6 Receptor Antagonist Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global IL-6 Receptor Antagonist Sales Market Share by Application (2021-2032)
- 7.2 Global IL-6 Receptor Antagonist Revenue by Application (2021-2032)
- 7.2.1 Global IL-6 Receptor Antagonist Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global IL-6 Receptor Antagonist Revenue Market Share by Application (2021-2032)
- 7.3 Global IL-6 Receptor Antagonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 IL-6 Receptor Antagonist Value Chain Analysis
- 8.1.1 IL-6 Receptor Antagonist Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 IL-6 Receptor Antagonist Production Mode & Process
- 8.2 IL-6 Receptor Antagonist Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 IL-6 Receptor Antagonist Distributors
- 8.2.3 IL-6 Receptor Antagonist Customers
9 Global IL-6 Receptor Antagonist Analyzing Market Dynamics
- 9.1 IL-6 Receptor Antagonist Industry Trends
- 9.2 IL-6 Receptor Antagonist Industry Drivers
- 9.3 IL-6 Receptor Antagonist Industry Opportunities and Challenges
- 9.4 IL-6 Receptor Antagonist Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst